Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Agilent Technologies (A) Exceeds Q4 Revenue Expectations with St - GuruFocus
Agilent Technologies (A) Exceeds Q4 Revenue Expectations with St GuruFocus
Agilent Technology Q4 Earnings Improve, Expects 6% To 8% Revenue Growth In Q1 - Nasdaq
Agilent Technology Q4 Earnings Improve, Expects 6% To 8% Revenue Growth In Q1 Nasdaq
Agilent Technologies Inc (A) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Agilent Technologies Inc (A) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... Yahoo Finance
Agilent Q4 2025 slides: Revenue beats guidance for sixth straight quarter - Investing.com
Agilent Q4 2025 slides: Revenue beats guidance for sixth straight quarter Investing.com
Agilent Technologies earnings beat by $0.01, revenue topped estimates By Investing.com - Investing.com Nigeria
Agilent Technologies earnings beat by $0.01, revenue topped estimates By Investing.com Investing.com Nigeria
Agilent (A) Exceeds Revenue Expectations with Strong Q4 Performa - GuruFocus
Agilent (A) Exceeds Revenue Expectations with Strong Q4 Performa GuruFocus
Agilent Technologies (A) Projects FY26 Revenue to Reach Up to $7 - GuruFocus
Agilent Technologies (A) Projects FY26 Revenue to Reach Up to $7 GuruFocus
Agilent Technologies earnings beat by $0.01, revenue topped estimates - Investing.com
Agilent Technologies earnings beat by $0.01, revenue topped estimates Investing.com
Earnings Flash (A) Agilent Technologies, Inc. Reports Q4 Revenue $1.86B, vs. FactSet Est of $1.83B - MarketScreener
Earnings Flash (A) Agilent Technologies, Inc. Reports Q4 Revenue $1.86B, vs. FactSet Est of $1.83B MarketScreener
Agilent beats quarterly revenue estimates on strong demand for lab tools - MarketScreener
Agilent beats quarterly revenue estimates on strong demand for lab tools MarketScreener
GSK, Anaptysbio sue each other over Jemperli revenue
As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.
Under RFK Jr., vaccine use slides while suspicion rises
Well into the first cold and flu season with Robert F. Kennedy Jr. as leader of HHS, vaccine revenue and uptake are down, while federal health officials continue to scr...
Moderna secures $1.5B lifeline as it looks to break even in 2028
At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set t...
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat - MSN
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat MSN
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat - Yahoo Finance
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat Yahoo Finance
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates - Nasdaq
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates Nasdaq
10X Genomics earnings beat by $0.07, revenue topped estimates - Investing.com
10X Genomics earnings beat by $0.07, revenue topped estimates Investing.com
10x Genomics (NASDAQ: TXG) guides fourth‑quarter revenue to $154–$158M after results - Stock Titan
10x Genomics (NASDAQ: TXG) guides fourth‑quarter revenue to $154–$158M after results Stock Titan
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page Thermo Fisher Core Tools & Instruments
Track Danaher Core Tools & Instruments
Track Agilent Core Tools & Instruments
Track Merck KGaA Core Tools & Instruments
Track Illumina Core Tools & Instruments
Track Waters Core Tools & Instruments
Track Bruker Core Tools & Instruments
Track Sartorius Core Tools & Instruments
Track Mettler Toledo Core Tools & Instruments
Track